American CryoStem Corporation Release: COO Anthony Dudzinski Was Interviewed On Uptick Network On Product Importance And Company Improvements

Eatontown, NJ Eatontown, NJ (UPTICK Newswire – August 14, 2017) - American CryoStem Corp. (OTC:Ticker CRYO) COO, Anthony (Tony) Dudzinski was interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. Mr. Dudzinski reviews the company’s background in regenerative medicine, the body’s ability to heal and improve self-sufficiency with its own tissues. He continued explaining the roll the company’s 17 patents play in the course of the company’s procedures. Mr. Dudzinski elaborated on the strategy of expansion to affiliates internationally in Hong Kong and Japan and the positive impact this will have on the company’s revenue development.

In closing Mr. Dudzinski stated, “We have developed a a unique cellular processing platform of our development and patented technology for licensing to generate stable revenues. Moving forward and we believe the licensing revenue will assist American CryoStem in supporting itself without having to continually go back to the well, increase float and increase dilution to existing shareholders,” Mr. Dudzinski continued, “we have a great set of core shareholders our strategy is to move forward and increase the value for our investors.”

To listen to the interview please click the link

The interview was paid and approved by American Cryostem Corp. The distribution was sent out to the Uptick Network Stock Day Radio show, sponsors, its affiliates and social media distribution platforms.

About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For more information, please visit: and

Forward Looking-Statement
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.


Phone: (732) 747-1007

Phone: (732) 747-1007

Back to news